Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module

Area of Science:

• Oncology
• Biochemistry
• Metabolism

Background:

• Phenformin, an antidiabetic drug, exhibits significant anticancer properties across various tumor types.
• The precise molecular mechanisms underlying phenformin's therapeutic effects in cancer remain largely unelucidated.
• Understanding these mechanisms is crucial for developing novel cancer therapies.

Purpose of the Study:

• To investigate the mechanism of action of phenformin in Shh medulloblastoma.
• To identify the key molecular targets and pathways involved in phenformin's anticancer activity.
• To explore the potential of targeting redox pathways and corepressor interactions for cancer treatment.

Main Methods:

• Utilized Shh medulloblastoma as a model system.
• Assessed phenformin's effects at clinically relevant concentrations.
• Investigated redox-dependent mechanisms and mitochondrial complex I activity.
• Examined the role of mitochondrial glycerophosphate dehydrogenase (mGPD) and NADH levels.
• Analyzed the association between corepressor CtBP2 and Gli1.
• Performed experiments involving CtBP2 ablation in mice.

Main Results:

• Phenformin demonstrated a significant therapeutic effect in Shh medulloblastoma via a redox-dependent, complex I-independent pathway.
• Phenformin inhibited mGPD, leading to increased intracellular NADH.
• mGPD inhibition mimicked phenformin's action, promoting CtBP2-Gli1 association and suppressing Hh transcriptional output.
• Ablation of CtBP2 abolished the therapeutic efficacy of phenformin in vivo.

Conclusions:

• Phenformin exerts its anticancer effects through a novel biguanide-mediated redox/corepressor interplay.
• Inhibition of mGPD and subsequent modulation of NADH levels are critical for phenformin's activity.
• The CtBP2-Gli1 interaction is a key downstream target of phenformin's mechanism.
• This interplay represents a potential therapeutic target for various cancers.